<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386708</url>
  </required_header>
  <id_info>
    <org_study_id>SCLnow-XY-01</org_study_id>
    <nct_id>NCT03386708</nct_id>
  </id_info>
  <brief_title>the Safety/Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Healing Poor After Uterus Injury</brief_title>
  <official_title>A Clinical Research on the Safety/Efficacy of Human Umbilical Cord Mesenchymal Stem Cell (hUC-MSC) Therapy for Patients With Healing Poor After Uterus Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sclnow Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sclnow Biotechnology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is verify the efficacy and safety of Human Umbilical Cord
      Mesenchymal Stem Cells (UC-MSC) therapy for patients with Healing Poor after Uterus Injury,
      and exploring the possible mechanisms of umbilical cord mesenchymal stem cell therapy in
      Healing Poor After Uterus Injury disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a random, open label, and parallel controled experiment. 40 patients are selected and
      sign consent forms, then divided into four groups. Doctors collect the basic information of
      patient (including age,height, mental condition, vital sign, history of disease,
      pharmaco-history, and so on.), evaluate the symptom of healing Poor after Uterus Injury
      (Menstrual conditions, Visual analogue scale, pregnancies).

      All patients receive laboratory and image examination as baseline. Then, cell treatment will
      be given based on the clinical protocol. Doctors have follow-up visit on 1, 2, 3, 6, and 12
      month after treatment, and do efficacy evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intrauterine adhesion patients efficacy evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate the efficacy by calculating the thickness of endometrium, the equation is, Efficacy = (thickness of endometrium after treatment - thickness of endometrium before treatment)/thickness of endometrium before treatment * 100%
Classified the efficacy in 4 grade as follow, A. Recovery, efficacy 86% - 100%; B. Obvious improve, efficacy 46% - 85%; C. Improve, efficacy 16% -45%; D. Invalid, efficacy &lt; 16% Grade A, B, and C is proposed to be effective.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incision lacuna and incision diverticulum patients efficacy evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate the efficacy by calculating the 50% or more reduction, the equation is, Efficacy = (Area of lacuna and diverticulum after treatment - Area of lacuna and diverticulum after treatment before treatment)/Area of lacuna and diverticulum before treatment * 100%.
Classified the efficacy in 4 grade as follow, A. Recovery, efficacy 86% - 100%; B. Obvious improve, efficacy 46% - 85%; C. Improve, efficacy 16% -45%; D. Invalid, efficacy &lt; 16% Grade A, B, and C is proposed to be effective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound of uterus evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Ultrasound of uterus. Compare with the baseline images, evaluate the changes/improvement after cell treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hysteroscopy evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Do hysteroscopy examination, compare with the baseline images, evaluate the change/improvement after cell treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>12 months</time_frame>
    <description>Measure the pain score of patients by Visual Analog Score (VAS) for pain</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Uterus; Injury</condition>
  <arm_group>
    <arm_group_label>hUC-MSC intrauterine injection group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human umbilical cord mesenchymal stem cells (hUC-MSC) (SCLnow 19#)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NS intrauterine injection group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline (NS) (2ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hUC-MSC intravenous injection group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Umbilical cord mesenchymal stem cells (SCLnow 19#)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NS intravenous injection group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline (NS) (30ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intrauterine injection</intervention_name>
    <description>intrauterine injection with umbilical cord mesenchymal stem cell (SCLnow 19#); one time/ 15 days, total 4 times</description>
    <arm_group_label>hUC-MSC intrauterine injection group</arm_group_label>
    <arm_group_label>NS intrauterine injection group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intravenous injection</intervention_name>
    <description>intravenous injection with umbilical cord mesenchymal stem cell (SCLnow 19#); one time/ 15 days, total 4 times</description>
    <arm_group_label>hUC-MSC intravenous injection group</arm_group_label>
    <arm_group_label>NS intravenous injection group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>umbilical cord mesenchymal stem cell</intervention_name>
    <description>Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), intrauterine injection: 2 * 10^7 cells (2ml)/ intravenous injection: 4 * 10^7 cells (30ml)</description>
    <arm_group_label>hUC-MSC intrauterine injection group</arm_group_label>
    <arm_group_label>hUC-MSC intravenous injection group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline (NS)</intervention_name>
    <description>Treat patient with Normal saline (NS): 2ml/30ml</description>
    <arm_group_label>NS intrauterine injection group</arm_group_label>
    <arm_group_label>NS intravenous injection group</arm_group_label>
    <other_name>placebo group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, with BMI 19-25 kg/m^2

          -  Meet the clinical standard of Healing Poor After Uterus Injury

          -  Non smoker

          -  Do not accept stem cells treatment in 6 months

          -  Participants or their family members sign the consent form of this study

        Exclusion Criteria:

          -  Pregnant or breast feeding women

          -  Age &lt;18 or &gt;50

          -  Refuse to sign the consent form

          -  Patients with underlying risk of medical disease history: history of diabetes, serious
             cardiovascular disease, severe infection, alimentary tract hemorrhage, etc.

          -  Serum with HIV, syphilis antibody positive

          -  Severe mental disease, cognitive disorder patients

          -  Other severe system or organ organic disease

          -  Participate other clinical experiments in 3 months

          -  Ovarian and pituitary dysfunction diseases

          -  With some other conditions that doctor propose not to participate
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weishe Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Guo</last_name>
    <phone>861064368977</phone>
    <email>georgeguo@sclnow.com</email>
  </overall_contact>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healing Poor After Uterus Injury, Mesenchymal Stem Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

